• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,550.25 918.60
( 1.20%)
Global Indices
Nasdaq
48,208.69 277.76
(0.58%)
Dow Jones
6,845.97 42.16
(0.62%)
Hang Seng
56,916.27 1,020.95
(1.83%)
Nikkei 225
10,596.33 -7.15
(-0.07%)
Forex
USD-INR
92.44 -0.46
(-0.50%)
EUR-INR
107.96 0.52
(0.48%)
GBP-INR
124.05 0.88
(0.72%)
JPY-INR
0.58 0.00
(0.32%)

EQUITY - MARKET SCREENER

Gufic BioSciences Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
509079
INE742B01025
62.6776943
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
GUFICBIO
59.27
2995.44
EPS(TTM)
Face Value()
Div & Yield %
5.04
1
0.03
 

Force Motors’ February 2026 sales rise 8% YoY
Mar 02,2026
The company’s domestic sales grew 8.63% to 3,825 units in February 2026, compared with 3,521 units sold in February 2025.

Exports declined 17.72% to 65 units in February 2026, compared with 79 units in the same period last year.

Force Motors is engaged in manufacturing light commercial vehicles, utility vehicles, and engines. It is an automobile company with a focus on the design, development, and manufacture of a range of automotive components, aggregates, and vehicles.

The company reported a 252.1% year-on-year surge in consolidated net profit to Rs 406.15 crore in Q3 FY26, compared with Rs 115.34 crore in the corresponding quarter last year. Revenue from operations rose 12.7% to Rs 2,128.56 crore in Q3 FY26 as against Rs 1,889.49 crore in Q3 FY25.

The counter slipped 3.35% to Rs 23,510 on the BSE.